Rituximab alleviates pediatric systemic lupus erythematosus associated refractory immune thrombocytopenia: a case-based review
We report a case of a child with SLE-associated ITP (SLE-ITP) who was successfully treated with rituximab. Rituximab is likely the most viable therapeutic option for refractory SLE-ITP. Furthermore, a comprehensive review of the relevant literature was performed and a concise overview of the pathogenesis and available treatment modalities for pediatric patients diagnosed with SLE and concurrent ITP was provided.
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Children | Corticosteroid Therapy | Lupus | Pediatrics | Rituxan | Thrombocytopenia